Vasodynamics clinical study results available

VasoDynamics Ltd, the pharmaceutical company developing patient-friendly therapies for the prevention of debilitating side-effects induced by anti-cancer treatments, is pleased to announce that the full clinical trial report has been completed. A summary of the NG11-2-P1b clinical study results is now publicly released on the VasoDynamics website. NG11-2 is an oral topical prescription drug to reduce and prevent severe Radiation-Induced Oral Mucositis (RIOM). Further details will also be available on public domains such as ISRCTN registry and clinical trials.gov website .

Dr Ningfeng Fiona Li, CEO of VasoDynamics, said:

From the readout of the Phase-Ib trial, NG11-2 oral topical solution is well tolerated and shows positive signals to enable the decision of progressing into a pivotal trial. We are delighted to release the existing results of the NG11-2 Phase 1b study, and we welcome further funding and partnerships to support moving the NG11-2 product into a larger scale pivotal trial and market approval.